ArticleGynecologic oncology2026
Associations between obesity and outcomes in pembrolizumab-treated endometrial cancer.
Article in Gynecologic oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Understanding the mechanisms underlying obesity induced tumorigenesis: therapeutic perspectives to manage dysregulated lipid metabolism.Discover oncology · 2026Review
- Endocrine Therapy for Endometrial Carcinoma: Current Evidence, Resistance Mechanisms, and Biomarker-Driven Patient Selection.Current oncology (Toronto, Ont.) · 2026Review
- Temporal Trends and Model-Based Projections of Female-Specific Cancer Burden Among East Asian Women Aged 55 Years and Older: A GBD 2023 Analysis.International journal of women's health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundTo determine the association between obesity and pembrolizumab response in racially diverse cohort of patients with advanced and recurrent endometrial cancer (EC).
methodsWe conducted a retrospective review of patients with advanced or recurrent endometrial cancer receiving pembrolizumab. Baseline clinical, demographic and cancer characteristics were collected. Progression free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method and modeled via Cox regression. Covariate differences were assessed using the log-rank test.
resultsAmong the 179 patients, the median age was 65 years (IQR, 58-71 yrs) and the mean BMI was 33 (SD, 8.5). The cohort consisted of 55 Black patents (31 %) and 112 White patients (63 %); 99 patients (55 %) were obese. Forty-six patients received pembrolizumab alone, and 133 received combination therapy. Higher BMI was associated with shorter PFS (BMI >40: HR 1.91, CI 1.13-3.21, p = 0.014 and BMI 30-40: HR 1.55, CI 1.02-2.35, p = 0.041). In MMR stratified analysis, obesity was associated with lower response rates among patients with MMRp tumors (23.4 %; BMI ≥30 vs 40.0 %; BMI <30), whereas response remained high across BMI categories in MMRd tumors. In the subgroup treated with pembrolizumab and Lenvatinib (n = 79), both White and Black obese experienced worse PFS compared to White non-obese patients (p = 0.021 and p = 0.035, respectively). No significant differences in OS were observed between obese and non-obese groups.
conclusionsIn this diverse cohort, obesity was associated with worse PFS in patients treated with pembrolizumab for EC. MMRp tumors in obese patients had lowest response rates among subgroups. Further studies with long term follow up are needed to elucidate the biological mechanisms linking obesity to immunotherapy outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.